BriaCell Therapeutics Corp.
BCTXZ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCTXZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCTXZ
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a lead candidate Bria-IMT in a pivotal Phase 3 trial for metastatic breast cancer and a next-generation personalized off-the-shelf platform Bria-OTS+.
Key risk: Clinical-stage dependency
Market Cap
$671K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a lead candidate Bria-IMT in a pivotal Phase 3 trial for metastatic breast cancer and a next-generation personalized off-the-shelf platform Bria-OTS+.
- Lead candidate Bria-IMT is in a pivotal Phase 3 study (Bria-ABC) for metastatic breast cancer, with topline interim data expected in H1-2026 [news · published 2025-12-09].
- Final Phase 2 data for Bria-IMT showed median overall survival of 16.6 months with the Phase 3 formulation [news · published 2026-05-22].
- The Bria-OTS+ platform demonstrated early, potent, and durable activation of innate and adaptive immunity in preclinical models [news · published 2026-04-21].
- Manufacturing of clinical supplies for Bria-PROS+, a next-generation immunotherapy for prostate cancer, has been completed, with a Phase 1/2a study planned [news · published 2026-05-14].
- The Phase 3 study has been featured in Nature Medicine as a clinical trial to watch in 2026 [news · published 2025-12-18].
What works
- Bria-IMT has shown a median overall survival of 16.6 months in a final Phase 2 analysis, with positive quality-of-life data from the ongoing Phase 3 study [news · published 2026-05-22].
- The Bria-OTS+ platform provides early, potent, and durable activation of both innate and adaptive immunity, with serial killing activity across multiple tumor cell challenges [news · published 2026-04-21].
- The Phase 3 study has strong enrollment momentum, with over 160 patients enrolled and multiple prestigious clinical sites added, including NYU Langone Health and Penn Medicine [news · published 2026-05-07][news · published 2026-05-13].
- The company is expanding its pipeline with Bria-PROS+ for prostate cancer and an AI-driven small molecule collaboration with Receptor.AI [news · published 2026-05-14][news · published 2025-11-20].
What to weigh
- The company is still clinical-stage and has not yet commercialized any product, meaning it relies on successful trial outcomes and regulatory approvals [news · published 2026-04-21].
- The Phase 3 trial is ongoing and topline data is not yet available; interim results are expected in H1-2026, creating uncertainty [news · published 2025-12-09].
- Bria-IMT is being studied in heavily pre-treated metastatic breast cancer, a population with limited treatment options and high unmet need, which may affect enrollment and outcomes [news · published 2026-05-22].
- The Bria-OTS+ platform is still in preclinical stages, and clinical validation has not yet been established [news · published 2026-04-21].
From the filings
Quoted directly from source documents.
Bria-IMT Phase 2 median overall survival is 16.6 months
“Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation)”
News · May 22, 2026
Bria-OTS+ platform activates innate and adaptive immunity
“Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in in-vitro cancer cell line models”
News · April 21, 2026
Phase 3 topline data expected in H1-2026
“BriaCell anticipates reporting top line data as early as H1-2026”
News · December 18, 2025
Manufacturing of Bria-PROS+ clinical supplies completed
“BriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in prostate cancer in the coming months”
News · May 14, 2026
Risks & what to watch (4)›
Key risks
- Clinical-stage dependency — No approved products; success hinges on Phase 3 outcome and regulatory approvals [news · published 2026-04-21]
- Phase 3 data uncertainty — Topline interim data expected H1-2026; results may not meet endpoints [news · published 2025-12-09]
- Heavily pre-treated patient population — Metastatic breast cancer patients are heavily pre-treated, which may limit efficacy and enrollment [news · published 2026-05-22]
- Preclinical platform risk — Bria-OTS+ platform is preclinical; clinical validation is pending [news · published 2026-04-21]
What to watch
- Topline interim data from the Phase 3 Bria-IMT study, expected in H1-2026 [news · published 2025-12-09].
- Initiation of the Phase 1/2a study for Bria-PROS+ in prostate cancer [news · published 2026-05-14].
- Further clinical data presentations at major conferences, such as ASCO 2026 [news · published 2026-04-27].
- Progress of the AI-driven small molecule collaboration with Receptor.AI [news · published 2025-11-20].
Sources: News · Generated August 10, 2026 · How we verify sources →
Run BriaCell Therapeutics Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BriaCell Therapeutics Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$105K
| Holder | Shares | Value |
|---|---|---|
| heights capital management, inc | 540,098 | $76K |
| sabby management, llc | 206,753 | $29K |
Short Interest
- % of float
- -
- Days to cover
- —
- Shares short
- -
- Daily short volume (Aug 25, 2026)
- 75.5%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCTXZ short interestFrequently asked questions
What is the AI investment thesis for BriaCell Therapeutics Corp.?
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a lead candidate Bria-IMT in a pivotal Phase 3 trial for metastatic breast cancer and a next-generation personalized off-the-shelf platform Bria-OTS+.
Who is the CEO of BriaCell Therapeutics Corp.?
Dr. William V. Williams FCPA, M.D. is the chief executive officer of BriaCell Therapeutics Corp. (BCTXZ).
Where is BriaCell Therapeutics Corp. headquartered?
BriaCell Therapeutics Corp. (BCTXZ) is headquartered in West Vancouver, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.